Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
4.883
+0.133 (2.80%)
Nov 5, 2024, 1:16 PM EST - Market open

Company Description

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer.

Its lead product candidate is ELI-002, a multivalent lymph node–targeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations.

The company is also developing ELI-007, a multivalent lymph node–targeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph node–targeted AMP peptide vaccine to target p53 hotspot mutations.

The company is headquartered in Boston, Massachusetts.

Elicio Therapeutics, Inc.
Elicio Therapeutics logo
Country United States
Founded 2011
IPO Date Feb 5, 2021
Industry Biotechnology
Sector Healthcare
Employees 32
CEO Robert Connelly

Contact Details

Address:
451 D Street, 5th Floor
Boston, Massachusetts 02210
United States
Phone 857-209-0050
Website elicio.com

Stock Details

Ticker Symbol ELTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001555192
CUSIP Number 28657F103
ISIN Number US28657F1030
Employer ID 45-2966790
SIC Code 2834

Key Executives

Name Position
Robert T. Connelly Chief Executive Officer, President, Principal Accounting Officer, Principal Financial Officer and Director
Dr. Christopher M. Haqq M.D., Ph.D. Executive Vice President, Head of Research and Development and Chief Medical Officer
Prof. Darrell J. Irvine Ph.D. Co-Founder, Consultant, Board Observer and Chairman of Scientific Advisory Board
Michael DiVecchia Senior Vice President of Operations and Human Resources
Dr. Peter DeMuth Ph.D. Chief Scientific Officer
Megan C. Filoon General Counsel, Secretary and Compliance Officer
Esther Welkowsky Senior Vice President of Clinical Development
Joy Seymour Vice President and Head of Regulatory Affairs
Dr. Thian Kheoh Ph.D. Senior Vice President of Biometrics

Latest SEC Filings

Date Type Title
Nov 2, 2022 D/A Filing
Sep 13, 2022 RW Filing
May 27, 2022 D Notice of Exempt Offering of Securities
Nov 18, 2021 D/A Filing
Nov 12, 2021 D/A Filing
Oct 19, 2021 D Notice of Exempt Offering of Securities
Jul 13, 2021 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Jun 29, 2021 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Jun 28, 2021 S-1 General form for registration of securities under the Securities Act of 1933
Jun 9, 2021 DRS/A [Amend] [Cover] Draft Registration Statement